Abstract
Chronic low back pain (CLBP) syndrome represents one of the leading causes of long-term disability worldwide. The prevalence of CLBP has been rising significantly in relation to increasing average life expectancy. CLBP results from chronification of acute low back pain. There are many factors contributing to the CLBP crisis; common etiopathogenetic factors include e.g., functional blockage of intervertebral joints. The treatment of CLBP is complex. An important part of treatment consists of pain pharmacotherapy, for which several groups of drugs are used. The problem lies in the side effects of many of these traditionally used medications. Therefore, new and safer treatment methods are being sought. Innovative options for CLBP pharmacology include injections containing collagen, which can be combined with other traditionally used drugs, which helps reduce dosages and increase the overall safety of CLBP therapy.
Keywords: Chronic low back pain, chronic pain management, pharmacotherapy of chronic pain, safe therapy of pain, pain control, collagen-containing injections.
[1]
Balagué, F.; Mannion, A.F.; Pellisé, F.; Cedraschi, C. Non-specific low back pain. Lancet, 2012, 379(9814), 482-491.
[2]
Shmagel, A.; Foley, R.; Ibrahim, H. Epidemiology of chronic low back pain in US adults: Data from the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res. (Hoboken), 2016, 68(11), 1688-1694.
[3]
Juniper, M.; Le, T.K.; Mladsi, D. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: A literature-based review. Expert Opin. Pharmacother., 2009, 10(16), 2581-2592.
[4]
Freburger, J.K.; Holmes, G.M.; Agans, R.P.; Jackman, A.M.; Darter, J.D.; Wallace, A.S.; Castel, L.D.; Kalsbeek, W.D.; Carey, T.S. The rising prevalence of chronic low back pain. Arch. Intern. Med., 2009, 169(3), 251-258.
[5]
Dagenais, S.; Tricco, A.C.; Haldeman, S. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. Spine J., 2010, 10(6), 514-529.
[6]
Delitto, A.; George, S.Z.; Van Dillen, L.R.; Whitman, J.M.; Sowa, G.; Shekelle, P.; Denninger, T.R.; Godges, J.J. Low back pain. J. Orthop. Sports Phys. Ther., 2012, 42(4), A1-A57.
[7]
Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Phys. Ther., 2001, 81(10), 1641-1674.
[8]
Smart, K.M.; Blake, C.; Staines, A.; Thacker, M.; Doody, C. Mechanisms-based classifications of musculoskeletal pain: part 1 of 3: symptoms and signs of central sensitisation in patients with low back (± leg) pain. Man. Ther., 2012, 17(4), 336-344.
[9]
Garland, E.L. Pain processing in the human nervous system: A selective review of nociceptive and biobehavioral pathways. Prim. Care, 2012, 39(3), 561-571.
[10]
Nijs, J.; Malfliet, A.; Ickmans, K.; Baert, I.; Meeus, M. Treatment of central sensitization in patients with ‘unexplained’ chronic pain: an update. Expert Opin. Pharmacother., 2014, 15(12), 1671-1683.
[11]
Binder, D.S.; Nampiaparampil, D.E. The provocative lumbar facet joint. Curr. Rev. Musculoskelet. Med., 2009, 2(1), 15-24.
[12]
Cohen, S.P.; Raja, S.N. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. Anesthesiology, 2007, 106(3), 591-614.
[14]
Manchikanti, L.; Singh, V.; Pampati, V.; Damron, K.S.; Barnhill, R.C.; Beyer, C.; Cash, K.A. Evaluation of the relative contributions of various structures in chronic low back pain. Pain Physician, 2001, 4(4), 308-316.
[15]
Deyo, R.A.; Bryan, M.; Comstock, B.A.; Turner, J.A.; Heagerty, P.; Friedly, J.; Avins, A.L.; Nedeljkovic, S.S.; Nerenz, D.R.; Jarvik, J.G. Trajectories of symptoms and function in older adults with low back disorders. Spine (Phila Pa 1976.), 2015, 40(17), 1352-1362.
[16]
Amirdelfan, K.; McRoberts, P.; Deer, T.R. The differential diagnosis of low back pain: A primer on the evolving paradigm. Neuromodulation, 2014, 17(Suppl.), 211-217.
[17]
Davis, P.C.; Wippold, F.J., II; Brunberg, J.A.; Cornelius, R.S.; De La Paz, R.L.; Dormont, P.D.; Gray, L.; Jordan, J.E.; Mukherji, S.K.; Seidenwurm, D.J.; Turski, P.A.; Zimmerman, R.D.; Sloan, M.A. ACR appropriateness criteria on low back pain. J. Am. Coll. Radiol., 2009, 6(6), 401-407.
[18]
Chou, R.; Qaseem, A.; Snow, V.; Casey, D.; Cross, J.T., Jr; Shekelle, P.; Owens, D.K. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann. Intern. Med., 2007, 147(7), 478-491.
[19]
Tan, A.; Zhou, J.; Kuo, Y.F.; Goodwin, J.S. Variation among primary care physicians in the use of imaging for older patients with acute low back pain. J. Gen. Intern. Med., 2016, 31(2), 156-163.
[20]
Boden, S.D.; Davis, D.O.; Dina, T.S.; Patronas, N.J.; Wiesel, S.W. Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation. J. Bone Joint Surg. Am., 1990, 72(3), 403-408.
[21]
Monie, A.P.; Fazey, P.J.; Singer, K.P. Low back pain misdiagnosis or missed diagnosis: Core principles. Man. Ther., 2016, 22, 68-71.
[22]
Allegri, M.; Montella, S.; Salici, F.; Valente, A.; Marchesini, M.; Compagnone, C.; Baciarello, M.; Manferdini, M.E.; Fanelli, G. Mechanisms of low back pain: A guide for diagnosis and therapy. F1000 Res., 2016, 5, 5.
[23]
Graham, G.G.; Davies, M.J.; Day, R.O.; Mohamudally, A.; Scott, K.F. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology, 2013, 21(3), 201-232.
[24]
Jaeschke, H. Acetaminophen: Dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig. Dis., 2015, 33(4), 464-471.
[25]
Machado, G.C.; Maher, C.G.; Ferreira, P.H.; Pinheiro, M.B.; Lin, C.W.; Day, R.O.; McLachlan, A.J.; Ferreira, M.L. Efficacy and safety of paracetamol for spinal pain and osteo-arthritis: Systematic review and meta-analysis of randomised placebo controlled trials. Bri Ed. J., 2015, 350, 1225.
[26]
Enthoven, W.T.; Roelofs, P.D.; Deyo, R.A.; van Tulder, M.W.; Koes, B.W. Non-steroidal anti-inflammatory drugs for chronic low back pain., Cochrane Database Syst. Rev.,. 2016. 2CD012087
[27]
Baron, R.; Binder, A.; Attal, N.; Casale, R.; Dickenson, A.H.; Treede, R.D. Neuropathic low back pain in clinical practice. Eur. J. Pain, 2016, 20(6), 861-873.
[28]
Gurwitz, J.H.; Everitt, D.E.; Monane, M.; Glynn, R.J.; Choodnovskiy, I.; Beaudet, M.P.; Avorn, J. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J. Gerontol. A Biol. Sci. Med. Sci., 1996, 51(2), M74-M79.
[29]
Pavlicević, I.; Kuzmanić, M.; Rumboldt, M.; Rumboldt, Z. Interaction between antihypertensives and NSAIDs in primary care: A controlled trial. Can. J. Clin. Pharmacol., 2008, 15(3), e372-e382.
[30]
Snowden, S.; Nelson, R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol. Rev., 2011, 19(4), 184-191.
[31]
Oka, Y.; Okamoto, K.; Kawashita, N.; Shirakuni, Y.; Takagi, T. Meta-analysis of the risk of upper gastrointestinal hemorrhage with combination therapy of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs. Biol. Pharm. Bull., 2014, 37(6), 947-953.
[32]
Anglin, R.; Yuan, Y.; Moayyedi, P.; Tse, F.; Armstrong, D.; Leontiadis, G.I. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: A systematic review and meta-analysis. Am. J. Gastroenterol., 2014, 109(6), 811-819.
[33]
Warkentin, A.E.; Donadini, M.P.; Spencer, F.A.; Lim, W.; Crowther, M. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: A systematic review and meta-analysis. J. Thromb. Haemost., 2012, 10(4), 512-520.
[34]
Machado, G.C.; Maher, C.G.; Ferreira, P.H.; Day, R.O.; Pinheiro, M.B.; Ferreira, M.L. Non-steroidal anti-inflammatory drugs for spinal pain: A systematic review and meta-analysis. Ann. Rheum. Dis., 2017, 76(7), 1269-1278.
[35]
Stamer, U.M.; Stüber, F. The pharmacogenetics of analgesia. Expert Opin. Pharmacother., 2007, 8(14), 2235-2245.
[36]
Farquhar-Smith, P.; Gubbay, A. Tramadol and acetaminophen combination for chronic non-cancer pain. Expert Opin. Pharmacother., 2013, 14(16), 2297-2304.
[37]
Mattia, C.; Coluzzi, F. A look inside the association codeine-paracetamol: Clinical pharmacology supports analgesic efficacy. Eur. Rev. Med. Pharmacol. Sci., 2015, 19(3), 507-516.
[38]
Chaparro, L.E.; Furlan, A.D.; Deshpande, A.; Mailis-Gagnon, A.; Atlas, S.; Turk, D.C. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst. Rev., 2013, (8), CD004959.
[39]
Reinecke, H.; Weber, C.; Lange, K.; Simon, M.; Stein, C.; Sorgatz, H. Analgesic efficacy of opioids in chronic pain: Recent meta-analyses. Br. J. Pharmacol., 2015, 172(2), 324-333.
[40]
Abdel Shaheed, C.; Maher, C.G.; Williams, K.A.; Day, R.; McLachlan, A.J. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: A systematic review and meta-analysis. JAMA Intern. Med., 2016, 176(7), 958-968.
[41]
Chey, W.D.; Webster, L.; Sostek, M.; Lappalainen, J.; Barker, P.N.; Tack, J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N. Engl. J. Med., 2014, 370(25), 2387-2396.
[42]
Davis, M.P.; Goforth, H.W. Oxycodone with an opioid receptor antagonist: A review. J. Opioid. Manag., 2016, 12(1), 67-85.
[43]
Chung, J.W.; Zeng, Y.; Wong, T.K. Drug therapy for the treatment of chronic nonspecific low back pain: Systematic review and meta-analysis. Pain Physician, 2013, 16(6), E685-E704.
[44]
Finnerup, N.B.; Attal, N. Pharmacotherapy of neuropathic pain: Time to rewrite the rulebook? Pain Manag., 2016, 6(1), 1-3.
[45]
Urquhart, D.M.; Hoving, J.L.; Assendelft, W.W.; Roland, M.; van Tulder, M.W. Antidepressants for non-specific low back pain. Cochrane Database Syst. Rev., 2008, (1), CD001703.
[46]
Abdel Shaheed, C.; Maher, C.G.; Williams, K.A.; McLachlan, A.J. Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis. Eur. J. Pain, 2017, 21(2), 228-237.
[47]
Keitel, W.; Frerick, H.; Kuhn, U.; Schmidt, U.; Kuhlmann, M.; Bredehorst, A. Capsicum pain plaster in chronic non-specific low back pain. Arzneimittelforschung, 2001, 51(11), 896-903.
[48]
Zhang, B.; Li, J.B.; Zhang, D.M.; Ding, Y.; Du, G.H. Analgesic and anti-inflammatory activities of a fraction rich in gaultherin isolated from Gaultheria yunnanensis (FRANCH.) REHDER. Biol. Pharm. Bull., 2007, 30(3), 465-469.
[49]
Ohta, T.; Imagawa, T.; Ito, S. Involvement of transient receptor potential vanilloid subtype 1 in analgesic action of methylsalicylate. Mol. Pharmacol., 2009, 75(2), 307-317.
[50]
Galer, B.S.; Gammaitoni, A.R.; Oleka, N.; Jensen, M.P.; Argoff, C.E. Use of the lidocaine patch 5% in reducing intensity of vari-ous pain qualities reported by patients with low-back pain. Curr. Med. Res. Opin., 2004. 20(Suppl), 2S5-S12
[51]
Casale, R.; Polati, E.; Schweiger, V.; Coluzzi, F.; Bhaskar, A.; Consalvo, M. [Localized neuropathic pain--5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience].Minerva Med. 2014, 105(3), 177-195.
[52]
Waseem, Z.; Boulias, C.; Gordon, A.; Ismail, F.; Sheean, G.; Furlan, A.D. Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst. Rev., 2011, (1), CD008257.
[53]
Valat, J.P.; Rozenberg, S. Local corticosteroid injections for low back pain and sciatica. Joint Bone Spine, 2008, 75(4), 403-407.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
38
5
2
1